Figure 1.

Fluorodeoxyglucose-positron emission tomography-computed tomography images before and after selinexor therapy. A. A positron emission tomography-computed tomography (PET-CT) image performed 3 months after chimeric antigen receptor T (CAR-T) cell therapy demonstrating progressive disease with pathological uptake in a mediastinal lymph node and in retroperitoneal, mesenteric and pelvic masses, obstructing urine flow from the left kidney (dashed line). B. A PET-CT image performed 3 months after selinexor initiation, demonstrating marked improvement with small foci of increased fluorodeoxyglucose (FDG) uptake (Deauville score =4) in residual mesenteric and retroperitoneal masses (solid line), and a new uptake focus above the urinary bladder. C. A PET-CT image performed 6 months after allogeneic stem cell transplantation (allo-SCT) and 11 months after selinexor initiation, demonstrating a complete metabolic response.